Q BioMed Inc.
Q BioMed Inc. QBIO Peers
See (QBIO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| QBIO | $0.00 | +0.00% | 14.5K | N/A | -$0.02 | N/A |
| NONOF | $68.97 | +2.03% | 303.6B | 18.89 | $3.62 | +2.41% |
| CSLLY | $79.37 | +0.80% | 153.5B | 29.13 | $2.72 | +1.68% |
| CMXHF | $151.02 | -7.39% | 73.1B | 27.71 | $5.45 | +1.83% |
| UCBJF | $199.89 | +0.00% | 38B | 31.78 | $6.29 | +0.79% |
| UCBJY | $98.22 | -0.03% | 37.3B | 31.17 | $3.15 | +0.80% |
| ARGNF | $547.60 | +0.08% | 33.4B | 33.35 | $16.42 | N/A |
| ODTC | $22,005.00 | +29.44% | 24.1B | 1.07 | $20,580.00 | N/A |
| IVBXF | $10.24 | -1.54% | 16.9B | -1024.00 | -$0.01 | N/A |
| WXXWY | $6.45 | -1.07% | 13.3B | 29.30 | $0.22 | N/A |
Stock Comparison
QBIO vs NONOF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, NONOF has a market cap of 303.6B. Regarding current trading prices, QBIO is priced at $0.00, while NONOF trades at $68.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas NONOF's P/E ratio is 18.89. In terms of profitability, QBIO's ROE is +0.44%, compared to NONOF's ROE of +0.81%. Regarding short-term risk, QBIO is less volatile compared to NONOF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs CSLLY Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, CSLLY has a market cap of 153.5B. Regarding current trading prices, QBIO is priced at $0.00, while CSLLY trades at $79.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas CSLLY's P/E ratio is 29.13. In terms of profitability, QBIO's ROE is +0.44%, compared to CSLLY's ROE of +0.26%. Regarding short-term risk, QBIO is less volatile compared to CSLLY. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs CMXHF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, CMXHF has a market cap of 73.1B. Regarding current trading prices, QBIO is priced at $0.00, while CMXHF trades at $151.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas CMXHF's P/E ratio is 27.71. In terms of profitability, QBIO's ROE is +0.44%, compared to CMXHF's ROE of +0.15%. Regarding short-term risk, QBIO and CMXHF have similar daily volatility (0.00).
QBIO vs UCBJF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, UCBJF has a market cap of 38B. Regarding current trading prices, QBIO is priced at $0.00, while UCBJF trades at $199.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas UCBJF's P/E ratio is 31.78. In terms of profitability, QBIO's ROE is +0.44%, compared to UCBJF's ROE of +0.03%. Regarding short-term risk, QBIO is less volatile compared to UCBJF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs UCBJY Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, UCBJY has a market cap of 37.3B. Regarding current trading prices, QBIO is priced at $0.00, while UCBJY trades at $98.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas UCBJY's P/E ratio is 31.17. In terms of profitability, QBIO's ROE is +0.44%, compared to UCBJY's ROE of +0.03%. Regarding short-term risk, QBIO is less volatile compared to UCBJY. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs ARGNF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, ARGNF has a market cap of 33.4B. Regarding current trading prices, QBIO is priced at $0.00, while ARGNF trades at $547.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas ARGNF's P/E ratio is 33.35. In terms of profitability, QBIO's ROE is +0.44%, compared to ARGNF's ROE of +0.16%. Regarding short-term risk, QBIO and ARGNF have similar daily volatility (0.00).
QBIO vs ODTC Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, ODTC has a market cap of 24.1B. Regarding current trading prices, QBIO is priced at $0.00, while ODTC trades at $22,005.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas ODTC's P/E ratio is 1.07. In terms of profitability, QBIO's ROE is +0.44%, compared to ODTC's ROE of +0.07%. Regarding short-term risk, QBIO and ODTC have similar daily volatility (0.00).
QBIO vs IVBXF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, IVBXF has a market cap of 16.9B. Regarding current trading prices, QBIO is priced at $0.00, while IVBXF trades at $10.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas IVBXF's P/E ratio is -1024.00. In terms of profitability, QBIO's ROE is +0.44%, compared to IVBXF's ROE of -0.01%. Regarding short-term risk, QBIO and IVBXF have similar daily volatility (0.00).
QBIO vs WXXWY Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, WXXWY has a market cap of 13.3B. Regarding current trading prices, QBIO is priced at $0.00, while WXXWY trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas WXXWY's P/E ratio is 29.30. In terms of profitability, QBIO's ROE is +0.44%, compared to WXXWY's ROE of +0.06%. Regarding short-term risk, QBIO is less volatile compared to WXXWY. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs SBMFF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, SBMFF has a market cap of 13B. Regarding current trading prices, QBIO is priced at $0.00, while SBMFF trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas SBMFF's P/E ratio is 72.56. In terms of profitability, QBIO's ROE is +0.44%, compared to SBMFF's ROE of +0.11%. Regarding short-term risk, QBIO is less volatile compared to SBMFF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs WXIBF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, WXIBF has a market cap of 12.9B. Regarding current trading prices, QBIO is priced at $0.00, while WXIBF trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas WXIBF's P/E ratio is 28.91. In terms of profitability, QBIO's ROE is +0.44%, compared to WXIBF's ROE of +0.06%. Regarding short-term risk, QBIO and WXIBF have similar daily volatility (0.00).
QBIO vs GNMSF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, GNMSF has a market cap of 12.6B. Regarding current trading prices, QBIO is priced at $0.00, while GNMSF trades at $205.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas GNMSF's P/E ratio is 12.03. In terms of profitability, QBIO's ROE is +0.44%, compared to GNMSF's ROE of +0.26%. Regarding short-term risk, QBIO and GNMSF have similar daily volatility (0.00).
QBIO vs SBHMY Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, SBHMY has a market cap of 8.5B. Regarding current trading prices, QBIO is priced at $0.00, while SBHMY trades at $9.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas SBHMY's P/E ratio is 32.69. In terms of profitability, QBIO's ROE is +0.44%, compared to SBHMY's ROE of +0.11%. Regarding short-term risk, QBIO is less volatile compared to SBHMY. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs TRSBF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, TRSBF has a market cap of 7.7B. Regarding current trading prices, QBIO is priced at $0.00, while TRSBF trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas TRSBF's P/E ratio is 27.08. In terms of profitability, QBIO's ROE is +0.44%, compared to TRSBF's ROE of +0.11%. Regarding short-term risk, QBIO is less volatile compared to TRSBF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs AKBLF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, AKBLF has a market cap of 6.3B. Regarding current trading prices, QBIO is priced at $0.00, while AKBLF trades at $28.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas AKBLF's P/E ratio is 42.73. In terms of profitability, QBIO's ROE is +0.44%, compared to AKBLF's ROE of +0.18%. Regarding short-term risk, QBIO and AKBLF have similar daily volatility (0.00).
QBIO vs TLPPF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, TLPPF has a market cap of 5.4B. Regarding current trading prices, QBIO is priced at $0.00, while TLPPF trades at $16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas TLPPF's P/E ratio is 177.78. In terms of profitability, QBIO's ROE is +0.44%, compared to TLPPF's ROE of +0.14%. Regarding short-term risk, QBIO and TLPPF have similar daily volatility (0.00).
QBIO vs ABCZF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, ABCZF has a market cap of 5.1B. Regarding current trading prices, QBIO is priced at $0.00, while ABCZF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas ABCZF's P/E ratio is 2225.00. In terms of profitability, QBIO's ROE is +0.44%, compared to ABCZF's ROE of -0.01%. Regarding short-term risk, QBIO and ABCZF have similar daily volatility (0.00).
QBIO vs INCPF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, INCPF has a market cap of 4.9B. Regarding current trading prices, QBIO is priced at $0.00, while INCPF trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas INCPF's P/E ratio is -108.67. In terms of profitability, QBIO's ROE is +0.44%, compared to INCPF's ROE of -0.05%. Regarding short-term risk, QBIO and INCPF have similar daily volatility (0.00).
QBIO vs GNNSF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, GNNSF has a market cap of 4.7B. Regarding current trading prices, QBIO is priced at $0.00, while GNNSF trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas GNNSF's P/E ratio is -27.50. In terms of profitability, QBIO's ROE is +0.44%, compared to GNNSF's ROE of -0.06%. Regarding short-term risk, QBIO is less volatile compared to GNNSF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs LABFF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, LABFF has a market cap of 4.6B. Regarding current trading prices, QBIO is priced at $0.00, while LABFF trades at $90.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas LABFF's P/E ratio is 28.95. In terms of profitability, QBIO's ROE is +0.44%, compared to LABFF's ROE of +0.39%. Regarding short-term risk, QBIO and LABFF have similar daily volatility (0.00).
QBIO vs ZLDPF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, ZLDPF has a market cap of 4.1B. Regarding current trading prices, QBIO is priced at $0.00, while ZLDPF trades at $57.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas ZLDPF's P/E ratio is -21.55. In terms of profitability, QBIO's ROE is +0.44%, compared to ZLDPF's ROE of -0.13%. Regarding short-term risk, QBIO is less volatile compared to ZLDPF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs CAMRF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, CAMRF has a market cap of 3.7B. Regarding current trading prices, QBIO is priced at $0.00, while CAMRF trades at $63.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas CAMRF's P/E ratio is 64.95. In terms of profitability, QBIO's ROE is +0.44%, compared to CAMRF's ROE of +0.14%. Regarding short-term risk, QBIO is less volatile compared to CAMRF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs REGMF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, REGMF has a market cap of 3.4B. Regarding current trading prices, QBIO is priced at $0.00, while REGMF trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas REGMF's P/E ratio is -13.32. In terms of profitability, QBIO's ROE is +0.44%, compared to REGMF's ROE of -0.48%. Regarding short-term risk, QBIO is less volatile compared to REGMF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs SHJBF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, SHJBF has a market cap of 3.1B. Regarding current trading prices, QBIO is priced at $0.00, while SHJBF trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas SHJBF's P/E ratio is -10.94. In terms of profitability, QBIO's ROE is +0.44%, compared to SHJBF's ROE of -0.27%. Regarding short-term risk, QBIO is less volatile compared to SHJBF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs TKBIF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, TKBIF has a market cap of 2.8B. Regarding current trading prices, QBIO is priced at $0.00, while TKBIF trades at $23.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas TKBIF's P/E ratio is 18.71. In terms of profitability, QBIO's ROE is +0.44%, compared to TKBIF's ROE of N/A. Regarding short-term risk, QBIO and TKBIF have similar daily volatility (0.00).
QBIO vs MPSYF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, MPSYF has a market cap of 2.8B. Regarding current trading prices, QBIO is priced at $0.00, while MPSYF trades at $73.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas MPSYF's P/E ratio is -12.13. In terms of profitability, QBIO's ROE is +0.44%, compared to MPSYF's ROE of +2.51%. Regarding short-term risk, QBIO is less volatile compared to MPSYF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs BVNKF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, BVNKF has a market cap of 2.1B. Regarding current trading prices, QBIO is priced at $0.00, while BVNKF trades at $26.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas BVNKF's P/E ratio is 10.37. In terms of profitability, QBIO's ROE is +0.44%, compared to BVNKF's ROE of +0.12%. Regarding short-term risk, QBIO is less volatile compared to BVNKF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs BVNRY Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, BVNRY has a market cap of 2.1B. Regarding current trading prices, QBIO is priced at $0.00, while BVNRY trades at $8.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas BVNRY's P/E ratio is 10.27. In terms of profitability, QBIO's ROE is +0.44%, compared to BVNRY's ROE of +0.12%. Regarding short-term risk, QBIO is less volatile compared to BVNRY. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs ASPHF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, ASPHF has a market cap of 2B. Regarding current trading prices, QBIO is priced at $0.00, while ASPHF trades at $5.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas ASPHF's P/E ratio is -32.36. In terms of profitability, QBIO's ROE is +0.44%, compared to ASPHF's ROE of -0.70%. Regarding short-term risk, QBIO is less volatile compared to ASPHF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs BTTAY Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, BTTAY has a market cap of 1.9B. Regarding current trading prices, QBIO is priced at $0.00, while BTTAY trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas BTTAY's P/E ratio is -67.31. In terms of profitability, QBIO's ROE is +0.44%, compared to BTTAY's ROE of +0.05%. Regarding short-term risk, QBIO is less volatile compared to BTTAY. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs ONTTF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, ONTTF has a market cap of 1.9B. Regarding current trading prices, QBIO is priced at $0.00, while ONTTF trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas ONTTF's P/E ratio is -9.19. In terms of profitability, QBIO's ROE is +0.44%, compared to ONTTF's ROE of -0.27%. Regarding short-term risk, QBIO is less volatile compared to ONTTF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs GLPGF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, GLPGF has a market cap of 1.8B. Regarding current trading prices, QBIO is priced at $0.00, while GLPGF trades at $27.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas GLPGF's P/E ratio is -8.79. In terms of profitability, QBIO's ROE is +0.44%, compared to GLPGF's ROE of -0.06%. Regarding short-term risk, QBIO is less volatile compared to GLPGF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs BRCTF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, BRCTF has a market cap of 1.7B. Regarding current trading prices, QBIO is priced at $0.00, while BRCTF trades at $19.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas BRCTF's P/E ratio is 18.42. In terms of profitability, QBIO's ROE is +0.44%, compared to BRCTF's ROE of -0.19%. Regarding short-term risk, QBIO is less volatile compared to BRCTF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs GENSF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, GENSF has a market cap of 1.7B. Regarding current trading prices, QBIO is priced at $0.00, while GENSF trades at $26.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas GENSF's P/E ratio is -325.12. In terms of profitability, QBIO's ROE is +0.44%, compared to GENSF's ROE of +0.01%. Regarding short-term risk, QBIO and GENSF have similar daily volatility (0.00).
QBIO vs PPTDF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, PPTDF has a market cap of 1.7B. Regarding current trading prices, QBIO is priced at $0.00, while PPTDF trades at $13.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas PPTDF's P/E ratio is 16.68. In terms of profitability, QBIO's ROE is +0.44%, compared to PPTDF's ROE of +0.26%. Regarding short-term risk, QBIO is less volatile compared to PPTDF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs BIESF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, BIESF has a market cap of 1.7B. Regarding current trading prices, QBIO is priced at $0.00, while BIESF trades at $32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas BIESF's P/E ratio is -44.44. In terms of profitability, QBIO's ROE is +0.44%, compared to BIESF's ROE of +0.05%. Regarding short-term risk, QBIO and BIESF have similar daily volatility (0.00).
QBIO vs PHMMF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, PHMMF has a market cap of 1.6B. Regarding current trading prices, QBIO is priced at $0.00, while PHMMF trades at $92.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas PHMMF's P/E ratio is 70.13. In terms of profitability, QBIO's ROE is +0.44%, compared to PHMMF's ROE of +0.10%. Regarding short-term risk, QBIO is less volatile compared to PHMMF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs CSBTF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, CSBTF has a market cap of 1.3B. Regarding current trading prices, QBIO is priced at $0.00, while CSBTF trades at $35.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas CSBTF's P/E ratio is -291.75. In terms of profitability, QBIO's ROE is +0.44%, compared to CSBTF's ROE of -0.15%. Regarding short-term risk, QBIO and CSBTF have similar daily volatility (0.00).
QBIO vs BRAXF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, BRAXF has a market cap of 1.3B. Regarding current trading prices, QBIO is priced at $0.00, while BRAXF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas BRAXF's P/E ratio is -0.03. In terms of profitability, QBIO's ROE is +0.44%, compared to BRAXF's ROE of -2.49%. Regarding short-term risk, QBIO is less volatile compared to BRAXF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs MEOBF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, MEOBF has a market cap of 1.2B. Regarding current trading prices, QBIO is priced at $0.00, while MEOBF trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas MEOBF's P/E ratio is -16.17. In terms of profitability, QBIO's ROE is +0.44%, compared to MEOBF's ROE of -0.15%. Regarding short-term risk, QBIO is less volatile compared to MEOBF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs ASCLF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, ASCLF has a market cap of 1.2B. Regarding current trading prices, QBIO is priced at $0.00, while ASCLF trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas ASCLF's P/E ratio is -31.37. In terms of profitability, QBIO's ROE is +0.44%, compared to ASCLF's ROE of -0.09%. Regarding short-term risk, QBIO and ASCLF have similar daily volatility (0.00).
QBIO vs NURPF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, NURPF has a market cap of 1.1B. Regarding current trading prices, QBIO is priced at $0.00, while NURPF trades at $8.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas NURPF's P/E ratio is 12.41. In terms of profitability, QBIO's ROE is +0.44%, compared to NURPF's ROE of +0.49%. Regarding short-term risk, QBIO is less volatile compared to NURPF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs SNBIF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, SNBIF has a market cap of 1.1B. Regarding current trading prices, QBIO is priced at $0.00, while SNBIF trades at $15.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas SNBIF's P/E ratio is -51.72. In terms of profitability, QBIO's ROE is +0.44%, compared to SNBIF's ROE of -0.92%. Regarding short-term risk, QBIO and SNBIF have similar daily volatility (0.00).
QBIO vs HBMHF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, HBMHF has a market cap of 931.6M. Regarding current trading prices, QBIO is priced at $0.00, while HBMHF trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas HBMHF's P/E ratio is 36.67. In terms of profitability, QBIO's ROE is +0.44%, compared to HBMHF's ROE of +0.02%. Regarding short-term risk, QBIO is less volatile compared to HBMHF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs PHGUF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, PHGUF has a market cap of 782.4M. Regarding current trading prices, QBIO is priced at $0.00, while PHGUF trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas PHGUF's P/E ratio is -57.50. In terms of profitability, QBIO's ROE is +0.44%, compared to PHGUF's ROE of -0.06%. Regarding short-term risk, QBIO is less volatile compared to PHGUF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs BPMUF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, BPMUF has a market cap of 752.7M. Regarding current trading prices, QBIO is priced at $0.00, while BPMUF trades at $61.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas BPMUF's P/E ratio is 8.63. In terms of profitability, QBIO's ROE is +0.44%, compared to BPMUF's ROE of -0.01%. Regarding short-term risk, QBIO and BPMUF have similar daily volatility (0.00).
QBIO vs CSPHF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, CSPHF has a market cap of 703M. Regarding current trading prices, QBIO is priced at $0.00, while CSPHF trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas CSPHF's P/E ratio is -51.80. In terms of profitability, QBIO's ROE is +0.44%, compared to CSPHF's ROE of -0.14%. Regarding short-term risk, QBIO is less volatile compared to CSPHF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs SOLTF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, SOLTF has a market cap of 597.3M. Regarding current trading prices, QBIO is priced at $0.00, while SOLTF trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas SOLTF's P/E ratio is -36.67. In terms of profitability, QBIO's ROE is +0.44%, compared to SOLTF's ROE of -0.07%. Regarding short-term risk, QBIO is less volatile compared to SOLTF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs BXPHF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, BXPHF has a market cap of 568.7M. Regarding current trading prices, QBIO is priced at $0.00, while BXPHF trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas BXPHF's P/E ratio is -29.00. In terms of profitability, QBIO's ROE is +0.44%, compared to BXPHF's ROE of -0.18%. Regarding short-term risk, QBIO is less volatile compared to BXPHF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs INRLF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, INRLF has a market cap of 527.2M. Regarding current trading prices, QBIO is priced at $0.00, while INRLF trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas INRLF's P/E ratio is -4.84. In terms of profitability, QBIO's ROE is +0.44%, compared to INRLF's ROE of -0.43%. Regarding short-term risk, QBIO is less volatile compared to INRLF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs IDRSF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, IDRSF has a market cap of 505.8M. Regarding current trading prices, QBIO is priced at $0.00, while IDRSF trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas IDRSF's P/E ratio is -1.45. In terms of profitability, QBIO's ROE is +0.44%, compared to IDRSF's ROE of +0.24%. Regarding short-term risk, QBIO is less volatile compared to IDRSF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs CKDXF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, CKDXF has a market cap of 485.9M. Regarding current trading prices, QBIO is priced at $0.00, while CKDXF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas CKDXF's P/E ratio is -1.26. In terms of profitability, QBIO's ROE is +0.44%, compared to CKDXF's ROE of +2.04%. Regarding short-term risk, QBIO is less volatile compared to CKDXF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs AAVXF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, AAVXF has a market cap of 461.9M. Regarding current trading prices, QBIO is priced at $0.00, while AAVXF trades at $7.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas AAVXF's P/E ratio is -2.11. In terms of profitability, QBIO's ROE is +0.44%, compared to AAVXF's ROE of -2.11%. Regarding short-term risk, QBIO is less volatile compared to AAVXF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs TBGNF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, TBGNF has a market cap of 433.7M. Regarding current trading prices, QBIO is priced at $0.00, while TBGNF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas TBGNF's P/E ratio is -0.25. In terms of profitability, QBIO's ROE is +0.44%, compared to TBGNF's ROE of N/A. Regarding short-term risk, QBIO and TBGNF have similar daily volatility (0.00).
QBIO vs VBIZF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, VBIZF has a market cap of 411.9M. Regarding current trading prices, QBIO is priced at $0.00, while VBIZF trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas VBIZF's P/E ratio is 19.80. In terms of profitability, QBIO's ROE is +0.44%, compared to VBIZF's ROE of -0.00%. Regarding short-term risk, QBIO and VBIZF have similar daily volatility (0.00).
QBIO vs PTCHF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, PTCHF has a market cap of 396.8M. Regarding current trading prices, QBIO is priced at $0.00, while PTCHF trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas PTCHF's P/E ratio is 7.87. In terms of profitability, QBIO's ROE is +0.44%, compared to PTCHF's ROE of -0.22%. Regarding short-term risk, QBIO is less volatile compared to PTCHF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs CLVLF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, CLVLF has a market cap of 361.9M. Regarding current trading prices, QBIO is priced at $0.00, while CLVLF trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas CLVLF's P/E ratio is 14.44. In terms of profitability, QBIO's ROE is +0.44%, compared to CLVLF's ROE of +0.19%. Regarding short-term risk, QBIO and CLVLF have similar daily volatility (0.00).
QBIO vs CLTEF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, CLTEF has a market cap of 351M. Regarding current trading prices, QBIO is priced at $0.00, while CLTEF trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas CLTEF's P/E ratio is -4.91. In terms of profitability, QBIO's ROE is +0.44%, compared to CLTEF's ROE of -0.43%. Regarding short-term risk, QBIO is less volatile compared to CLTEF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs NWBO Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, NWBO has a market cap of 347.5M. Regarding current trading prices, QBIO is priced at $0.00, while NWBO trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas NWBO's P/E ratio is -4.02. In terms of profitability, QBIO's ROE is +0.44%, compared to NWBO's ROE of +1.13%. Regarding short-term risk, QBIO is less volatile compared to NWBO. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs CLVLY Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, CLVLY has a market cap of 341.6M. Regarding current trading prices, QBIO is priced at $0.00, while CLVLY trades at $6.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas CLVLY's P/E ratio is 13.61. In terms of profitability, QBIO's ROE is +0.44%, compared to CLVLY's ROE of +0.19%. Regarding short-term risk, QBIO is less volatile compared to CLVLY. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs CYDY Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, CYDY has a market cap of 326M. Regarding current trading prices, QBIO is priced at $0.00, while CYDY trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas CYDY's P/E ratio is -13.22. In terms of profitability, QBIO's ROE is +0.44%, compared to CYDY's ROE of +0.07%. Regarding short-term risk, QBIO is less volatile compared to CYDY. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs IVEVF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, IVEVF has a market cap of 317.2M. Regarding current trading prices, QBIO is priced at $0.00, while IVEVF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas IVEVF's P/E ratio is -0.66. In terms of profitability, QBIO's ROE is +0.44%, compared to IVEVF's ROE of +1.67%. Regarding short-term risk, QBIO is less volatile compared to IVEVF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs PBBIF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, PBBIF has a market cap of 286.9M. Regarding current trading prices, QBIO is priced at $0.00, while PBBIF trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas PBBIF's P/E ratio is 266.67. In terms of profitability, QBIO's ROE is +0.44%, compared to PBBIF's ROE of +0.01%. Regarding short-term risk, QBIO is less volatile compared to PBBIF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs HLOSF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, HLOSF has a market cap of 282.6M. Regarding current trading prices, QBIO is priced at $0.00, while HLOSF trades at $2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas HLOSF's P/E ratio is -8.71. In terms of profitability, QBIO's ROE is +0.44%, compared to HLOSF's ROE of -1.30%. Regarding short-term risk, QBIO and HLOSF have similar daily volatility (0.00).
QBIO vs PRRUF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, PRRUF has a market cap of 277.5M. Regarding current trading prices, QBIO is priced at $0.00, while PRRUF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas PRRUF's P/E ratio is -9.50. In terms of profitability, QBIO's ROE is +0.44%, compared to PRRUF's ROE of -0.28%. Regarding short-term risk, QBIO is less volatile compared to PRRUF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs ORYZF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, ORYZF has a market cap of 249.8M. Regarding current trading prices, QBIO is priced at $0.00, while ORYZF trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas ORYZF's P/E ratio is -53.72. In terms of profitability, QBIO's ROE is +0.44%, compared to ORYZF's ROE of -0.05%. Regarding short-term risk, QBIO is less volatile compared to ORYZF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs NWPHF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, NWPHF has a market cap of 231.2M. Regarding current trading prices, QBIO is priced at $0.00, while NWPHF trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas NWPHF's P/E ratio is N/A. In terms of profitability, QBIO's ROE is +0.44%, compared to NWPHF's ROE of N/A. Regarding short-term risk, QBIO and NWPHF have similar daily volatility (0.00).
QBIO vs MDCLF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, MDCLF has a market cap of 230.7M. Regarding current trading prices, QBIO is priced at $0.00, while MDCLF trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas MDCLF's P/E ratio is -5.21. In terms of profitability, QBIO's ROE is +0.44%, compared to MDCLF's ROE of +0.60%. Regarding short-term risk, QBIO is less volatile compared to MDCLF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs SLNCF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, SLNCF has a market cap of 226.7M. Regarding current trading prices, QBIO is priced at $0.00, while SLNCF trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas SLNCF's P/E ratio is -3.14. In terms of profitability, QBIO's ROE is +0.44%, compared to SLNCF's ROE of -0.87%. Regarding short-term risk, QBIO is less volatile compared to SLNCF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs BOVNF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, BOVNF has a market cap of 216.4M. Regarding current trading prices, QBIO is priced at $0.00, while BOVNF trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas BOVNF's P/E ratio is -4.44. In terms of profitability, QBIO's ROE is +0.44%, compared to BOVNF's ROE of -0.50%. Regarding short-term risk, QBIO is less volatile compared to BOVNF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs RAONF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, RAONF has a market cap of 212M. Regarding current trading prices, QBIO is priced at $0.00, while RAONF trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas RAONF's P/E ratio is -20.33. In terms of profitability, QBIO's ROE is +0.44%, compared to RAONF's ROE of -0.71%. Regarding short-term risk, QBIO is less volatile compared to RAONF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs FPHAF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, FPHAF has a market cap of 209.5M. Regarding current trading prices, QBIO is priced at $0.00, while FPHAF trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas FPHAF's P/E ratio is -7.50. In terms of profitability, QBIO's ROE is +0.44%, compared to FPHAF's ROE of N/A. Regarding short-term risk, QBIO and FPHAF have similar daily volatility (0.00).
QBIO vs VSBC Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, VSBC has a market cap of 207M. Regarding current trading prices, QBIO is priced at $0.00, while VSBC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas VSBC's P/E ratio is N/A. In terms of profitability, QBIO's ROE is +0.44%, compared to VSBC's ROE of +0.00%. Regarding short-term risk, QBIO and VSBC have similar daily volatility (0.00).
QBIO vs FGHQF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, FGHQF has a market cap of 205.6M. Regarding current trading prices, QBIO is priced at $0.00, while FGHQF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas FGHQF's P/E ratio is 10.10. In terms of profitability, QBIO's ROE is +0.44%, compared to FGHQF's ROE of +0.00%. Regarding short-term risk, QBIO is less volatile compared to FGHQF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs HNSBF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, HNSBF has a market cap of 203.4M. Regarding current trading prices, QBIO is priced at $0.00, while HNSBF trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas HNSBF's P/E ratio is -2.34. In terms of profitability, QBIO's ROE is +0.44%, compared to HNSBF's ROE of +1.43%. Regarding short-term risk, QBIO is less volatile compared to HNSBF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs BSEM Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, BSEM has a market cap of 196.1M. Regarding current trading prices, QBIO is priced at $0.00, while BSEM trades at $11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas BSEM's P/E ratio is -21.05. In terms of profitability, QBIO's ROE is +0.44%, compared to BSEM's ROE of +1.50%. Regarding short-term risk, QBIO is less volatile compared to BSEM. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs BRIBF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, BRIBF has a market cap of 190.3M. Regarding current trading prices, QBIO is priced at $0.00, while BRIBF trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas BRIBF's P/E ratio is -2.60. In terms of profitability, QBIO's ROE is +0.44%, compared to BRIBF's ROE of -0.10%. Regarding short-term risk, QBIO is less volatile compared to BRIBF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs SPHDF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, SPHDF has a market cap of 189.9M. Regarding current trading prices, QBIO is priced at $0.00, while SPHDF trades at $14.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas SPHDF's P/E ratio is -3.28. In terms of profitability, QBIO's ROE is +0.44%, compared to SPHDF's ROE of +0.89%. Regarding short-term risk, QBIO is less volatile compared to SPHDF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs IPHYF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, IPHYF has a market cap of 179.7M. Regarding current trading prices, QBIO is priced at $0.00, while IPHYF trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas IPHYF's P/E ratio is -2.79. In terms of profitability, QBIO's ROE is +0.44%, compared to IPHYF's ROE of -1.81%. Regarding short-term risk, QBIO is less volatile compared to IPHYF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs NGENF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, NGENF has a market cap of 176.5M. Regarding current trading prices, QBIO is priced at $0.00, while NGENF trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas NGENF's P/E ratio is -8.66. In terms of profitability, QBIO's ROE is +0.44%, compared to NGENF's ROE of -2.23%. Regarding short-term risk, QBIO is less volatile compared to NGENF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs GNFTF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, GNFTF has a market cap of 176.3M. Regarding current trading prices, QBIO is priced at $0.00, while GNFTF trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas GNFTF's P/E ratio is 8.85. In terms of profitability, QBIO's ROE is +0.44%, compared to GNFTF's ROE of +0.27%. Regarding short-term risk, QBIO is less volatile compared to GNFTF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs ADOCY Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, ADOCY has a market cap of 170.4M. Regarding current trading prices, QBIO is priced at $0.00, while ADOCY trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas ADOCY's P/E ratio is -3.36. In terms of profitability, QBIO's ROE is +0.44%, compared to ADOCY's ROE of +1.73%. Regarding short-term risk, QBIO and ADOCY have similar daily volatility (0.00).
QBIO vs OPORF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, OPORF has a market cap of 164.9M. Regarding current trading prices, QBIO is priced at $0.00, while OPORF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas OPORF's P/E ratio is 12.00. In terms of profitability, QBIO's ROE is +0.44%, compared to OPORF's ROE of +0.42%. Regarding short-term risk, QBIO is less volatile compared to OPORF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs MLLCF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, MLLCF has a market cap of 155.6M. Regarding current trading prices, QBIO is priced at $0.00, while MLLCF trades at $4.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas MLLCF's P/E ratio is -1.99. In terms of profitability, QBIO's ROE is +0.44%, compared to MLLCF's ROE of -0.36%. Regarding short-term risk, QBIO is less volatile compared to MLLCF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs AVCTF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, AVCTF has a market cap of 155.1M. Regarding current trading prices, QBIO is priced at $0.00, while AVCTF trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas AVCTF's P/E ratio is -3.34. In terms of profitability, QBIO's ROE is +0.44%, compared to AVCTF's ROE of -1.24%. Regarding short-term risk, QBIO is less volatile compared to AVCTF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs SCNLF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, SCNLF has a market cap of 135.3M. Regarding current trading prices, QBIO is priced at $0.00, while SCNLF trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas SCNLF's P/E ratio is -4.35. In terms of profitability, QBIO's ROE is +0.44%, compared to SCNLF's ROE of +2.45%. Regarding short-term risk, QBIO is less volatile compared to SCNLF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs AAPGV Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, AAPGV has a market cap of 127.3M. Regarding current trading prices, QBIO is priced at $0.00, while AAPGV trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas AAPGV's P/E ratio is N/A. In terms of profitability, QBIO's ROE is +0.44%, compared to AAPGV's ROE of N/A. Regarding short-term risk, QBIO is less volatile compared to AAPGV. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs AMGXF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, AMGXF has a market cap of 127.1M. Regarding current trading prices, QBIO is priced at $0.00, while AMGXF trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas AMGXF's P/E ratio is -0.46. In terms of profitability, QBIO's ROE is +0.44%, compared to AMGXF's ROE of -0.24%. Regarding short-term risk, QBIO is less volatile compared to AMGXF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs PSTTF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, PSTTF has a market cap of 117.5M. Regarding current trading prices, QBIO is priced at $0.00, while PSTTF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas PSTTF's P/E ratio is -29.00. In terms of profitability, QBIO's ROE is +0.44%, compared to PSTTF's ROE of N/A. Regarding short-term risk, QBIO and PSTTF have similar daily volatility (0.00).
QBIO vs EPRXF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, EPRXF has a market cap of 108.3M. Regarding current trading prices, QBIO is priced at $0.00, while EPRXF trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas EPRXF's P/E ratio is -2.69. In terms of profitability, QBIO's ROE is +0.44%, compared to EPRXF's ROE of -0.85%. Regarding short-term risk, QBIO is less volatile compared to EPRXF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs ADOIF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, ADOIF has a market cap of 103.7M. Regarding current trading prices, QBIO is priced at $0.00, while ADOIF trades at $8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas ADOIF's P/E ratio is -2.59. In terms of profitability, QBIO's ROE is +0.44%, compared to ADOIF's ROE of +6.08%. Regarding short-term risk, QBIO and ADOIF have similar daily volatility (0.00).
QBIO vs JWCTF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, JWCTF has a market cap of 101.3M. Regarding current trading prices, QBIO is priced at $0.00, while JWCTF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas JWCTF's P/E ratio is -1.25. In terms of profitability, QBIO's ROE is +0.44%, compared to JWCTF's ROE of -0.47%. Regarding short-term risk, QBIO and JWCTF have similar daily volatility (0.00).
QBIO vs TRGNF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, TRGNF has a market cap of 92.4M. Regarding current trading prices, QBIO is priced at $0.00, while TRGNF trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas TRGNF's P/E ratio is -2.12. In terms of profitability, QBIO's ROE is +0.44%, compared to TRGNF's ROE of -3.14%. Regarding short-term risk, QBIO is less volatile compared to TRGNF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs CMVLF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, CMVLF has a market cap of 90.1M. Regarding current trading prices, QBIO is priced at $0.00, while CMVLF trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas CMVLF's P/E ratio is -1.87. In terms of profitability, QBIO's ROE is +0.44%, compared to CMVLF's ROE of -0.30%. Regarding short-term risk, QBIO is less volatile compared to CMVLF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs MCURF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, MCURF has a market cap of 86.5M. Regarding current trading prices, QBIO is priced at $0.00, while MCURF trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas MCURF's P/E ratio is -16.90. In terms of profitability, QBIO's ROE is +0.44%, compared to MCURF's ROE of -1.02%. Regarding short-term risk, QBIO is less volatile compared to MCURF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs ACHFF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, ACHFF has a market cap of 84.6M. Regarding current trading prices, QBIO is priced at $0.00, while ACHFF trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas ACHFF's P/E ratio is -42.67. In terms of profitability, QBIO's ROE is +0.44%, compared to ACHFF's ROE of +0.53%. Regarding short-term risk, QBIO is less volatile compared to ACHFF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs PBIGF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, PBIGF has a market cap of 84.4M. Regarding current trading prices, QBIO is priced at $0.00, while PBIGF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas PBIGF's P/E ratio is -7.22. In terms of profitability, QBIO's ROE is +0.44%, compared to PBIGF's ROE of -2.16%. Regarding short-term risk, QBIO is less volatile compared to PBIGF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs MSCLF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, MSCLF has a market cap of 83M. Regarding current trading prices, QBIO is priced at $0.00, while MSCLF trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas MSCLF's P/E ratio is 2.61. In terms of profitability, QBIO's ROE is +0.44%, compared to MSCLF's ROE of -0.74%. Regarding short-term risk, QBIO is less volatile compared to MSCLF. This indicates potentially lower risk in terms of short-term price fluctuations for QBIO.
QBIO vs KNTPF Comparison
QBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QBIO stands at 14.5K. In comparison, KNTPF has a market cap of 77M. Regarding current trading prices, QBIO is priced at $0.00, while KNTPF trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QBIO currently has a P/E ratio of N/A, whereas KNTPF's P/E ratio is -3.55. In terms of profitability, QBIO's ROE is +0.44%, compared to KNTPF's ROE of -4.62%. Regarding short-term risk, QBIO and KNTPF have similar daily volatility (0.00).